Sector News

Alexion appoints new senior VP for EMEAC region

February 6, 2018
Life sciences

Camillia HartvigAlexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

She will lead the commercial activities of the regional function from Alexion’s EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.

Regarding her new role, Hartvig said: “I am delighted to join the great team in this region, that is a strategic pillar for Alexion accounting for more than a third of Alexion’s global business, and look forward to stewarding the company’s growth and development hire in the years ahead.”

Hartvig, who has more than 20 years’ experience in the pharmaceutical industry, has worked in a broad spectrum of companies, including AstraZeneca, Novartis and Allergan.

Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.

She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.

Source: PMLive

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend